Navigation Links
Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
Date:4/28/2008

SANTA MONICA, Calif., April 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive. The cancer targets that the Company has chosen are ailments which Rh-Apo2L has shown the most efficacy and which have the most market potential. The Company previously announced that Rh-Apo2L testing results have shown strong efficacy in treating non-small cell lung cancer, non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer.

The Company intends to immediately file for Phase 3 clinical testing with the People's Republic of China's State Food and Drug Administration after the announcement of the findings from Phase 2 testing. The Company anticipates that the Chinese government will then allow for the commencement of Phase 3 testing within two to three months after the Phase 2 results are published. Phase 3 testing will entail large-volume tests on over 300 patients and is the last step before it may be commercially sold in the People's Republic of China.

About Rh-Apo2L- The Anti-Cancer Drug

Rh-Apo2L is a pioneering biotechnology gene therapy drug used to treat certain forms of cancer. This biopharmaceutical drug has gained the attention of researchers and clinical professionals throughout the People's Republic of China who are observing the drug for potential replacement of surgery and radiation therapy for cancer. Potentially, over 8 million lives can be saved each year in the People's Republic of China by this drug.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanc
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
2. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
5. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
6. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
7. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
9. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
10. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
11. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Apex Therapeutics ... BIO International Convention in Philadelphia, PA. , The presentation took place on ... outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome ... new insights on mechanics of fecal microbiota transplantation in C. difficile patients. , ... microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... AMSTERDAM, December 15, 2011 Amsterdam Molecular Therapeutics ... therapy, announced today that the Company has a negative equity ... of this negative equity position is in line with previous ... is exploring alternatives for additional financing. AMT announced ...
... discovery of a new way to tune and enhance thermal ... for a given material gives engineers a new tool ... and a number of other powered devices. The finding ... Li, associate professor of mechanical engineering at Vanderbilt University, and ...
... SHANGHAI, Dec. 14, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development outsourcing ... Morgan,s 30th Annual Healthcare Conference, to be held in ... Michael Xin Hui, founder and Chief Executive Officer of ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Announces Negative Equity Position 2Amsterdam Molecular Therapeutics Announces Negative Equity Position 3New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 2New method for enhancing thermal conductivity could cool computer chips, lasers and other devices 3
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... French . , Chicken sold in supermarkets, restaurants ... urinary tract infections (UTI), McGill researcher Amee Manges has discovered. ... in collaboration with the Public Health Agency of Canada and ... E. coli ( Escherichia coli ) bacteria originating from ...
... the first evidence from human research that blueberries ... other so-called phytochemicals improve memory. They said the ... to determine whether blueberries really deserve their growing reputation ... appears in ACS, Journal of Agricultural and Food ...
... a jury could decide a man,s guilt through mind reading? ... And what constitutes ,intent, to commit murder? These are ... inaugural issue of WIREs Cognitive Science, the latest interdisciplinary project ... the first two years. In the article "Neurolaw," ...
Cached Biology News:Retail meat linked to urinary tract infections: Strong new evidence 2Mind reading, brain fingerprinting and the law 2
... The nature of proteomics demands the ... The superior performance of the AXIMA-CFRplus with ... than 5 ppm) provides increased confidence in ... blanking for enhanced sensitivity, automated sample target ...
... Axima range, the AXIMA-CFR provides a ... sensitivity and mass range, and offers ... reflectron time-of-flight analysis. The unique patented ... of seamless PSD, providing efficient and ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
...
Biology Products: